Pancreatic Cancer

Oncology
110
Pipeline Programs
30
Companies
50
Clinical Trials
10 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
21
17
46
2
16
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1368%
Small Molecule
526%
Peptide
15%
+ 101 programs with unclassified modality

On Market (7)

Approved therapies currently available

U
CEFOXITINApproved
cefoxitin
Unknown Company
injection2009
U
CEFOXITIN IN PLASTIC CONTAINERApproved
cefoxitin
Unknown Company
intravenous2015
U
EFUDEXApproved
fluorouracil
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]topical1970
U
GEMCITABINEApproved
gemcitabine
Unknown Company
injection
Pfizer
GEMCITABINE HYDROCHLORIDEApproved
gemcitabine
Pfizer
injection2011
U
METHYLNALTREXONE BROMIDEApproved
methylnaltrexone bromide
Unknown Company
subcutaneous
U
TOLAKApproved
fluorouracil
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]topical2015

Competitive Landscape

59 companies ranked by most advanced pipeline stage

E
2 programs
1
1
DalteparinPhase 41 trial
fluorouracilPhase 31 trial
Active Trials
NCT00033735Completed158
NCT00966277Completed87Est. Sep 2014
Pfizer
PfizerNEW YORK, NY
1 program
1
1
gemcitabine hydrochloridePhase 21 trial
Active Trials
NCT00004861CompletedEst. Sep 2001
Verona Pharma
4 programs
1
1
gemcitabinePhase 31 trial
immunostimulating Interstitial Laser ThermotherapyPhase 11 trial
Barratt Simplified Measure of Social StatusN/A1 trial
Electrochemotherapy with BleomycinN/A1 trial
Active Trials
NCT04024345Unknown150Est. Dec 2021
NCT03225781Terminated1Est. Dec 2018
NCT02702986Completed10Est. Oct 2021
+1 more trials
Astex Pharmaceuticals
4 programs
1
3
fluorouracilPhase 31 trial
fluorouracilPhase 31 trial
gemcitabine hydrochloridePhase 31 trial
RubitecanPhase 2/31 trial
Active Trials
NCT00113256Terminated
NCT00005871Unknown
NCT00005870Unknown
+1 more trials
Astellas
3 programs
1
2
SetidegrasibPhase 32 trials
TarcevaPhase 32 trials
erlotinib hydrochloridePhase 11 trial
Active Trials
NCT00033241CompletedEst. Apr 2004
NCT07409272Recruiting614Est. Aug 2029
NCT05382559Recruiting681Est. Dec 2027
+2 more trials
DS
Daiichi SankyoChina - Shanghai
3 programs
2
1
exatecan mesylatePhase 31 trial
CS-1008Phase 21 trial
exatecan mesylatePhase 21 trial
Active Trials
NCT00521404Completed65Est. Aug 2010
NCT00003951Completed37Est. Apr 2005
NCT00023972CompletedEst. Apr 2005
Qilu Pharmaceutical
2 programs
1
1
QLS31905Phase 31 trial
CEND-1Phase 1/21 trial
Active Trials
NCT05052567CompletedEst. Jun 2024
NCT07079228RecruitingEst. Sep 2030
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
1
1
Methylnaltrexone bromidePhase 31 trial
Methylnaltrexone bromidePhase 2/31 trial
Active Trials
NCT04083651WithdrawnEst. Oct 2023
NCT04151719WithdrawnEst. Feb 2024
REVOLUTION Medicines
2 programs
2
RMC-6236Phase 31 trial
daraxonrasibPhase 31 trial
Active Trials
NCT06625320Active Not Recruiting501Est. Dec 2027
NCT07252232Recruiting500Est. Jul 2030
Providence Therapeutics
1 program
1
CefoxitinPhase 31 trial
Active Trials
NCT03269994CompletedEst. Jan 2025
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
1
CefoxitinPhase 3
AS
1 program
1
MasitinibPhase 3Small Molecule1 trial
Active Trials
NCT00789633CompletedEst. Aug 2012
Aptose Biosciences
1 program
1
Virulizin®Phase 31 trial
Active Trials
NCT00040092Completed
GS
Gilead SciencesFOSTER CITY, CA
6 programs
1
4
1
SimtuzumabPhase 2Monoclonal Antibody1 trial
90Y-hPAM4Phase 1/21 trial
90Y-hPAM4Phase 1/2
IMMU-107Phase 1/21 trial
IMMU-107Phase 1/2
+1 more programs
Active Trials
NCT02862535Terminated36Est. Oct 2019
NCT01803282Completed236Est. Apr 2019
NCT00597129Completed21Est. Oct 2007
+2 more trials
Heidelberg Pharma
5 programs
2
SBRTPhase 21 trial
gemcitabine hydrochloridePhase 21 trial
Carbon IonN/A1 trial
Six months supervised resistance trainingN/A1 trial
Surgical bypassN/A1 trial
Active Trials
NCT04194268Completed25Est. Nov 2025
NCT01977066Completed65Est. Dec 2016
NCT00753441Terminated24Est. Aug 2017
+2 more trials
M&
5 programs
1
1
3
ARQ 501 in combination with gemcitabinePhase 21 trial
UFT, LeucovorinPhase 21 trial
irofulvenPhase 21 trial
MK-0646Phase 1/21 trial
AS703569/gemcitabinePhase 11 trial
Active Trials
NCT01097512Completed66Est. Feb 2011
NCT00769483Completed81Est. Sep 2020
NCT00102700Completed66Est. Jan 2007
+2 more trials
Genentech
5 programs
1
4
AvastinPhase 21 trial
ErlotinibPhase 2Small Molecule1 trial
GemcitabinePhase 21 trial
PertuzumabPhase 2Monoclonal Antibody1 trial
Capecitabine, TarcevaPhase 11 trial
Active Trials
NCT00565487Completed15Est. Aug 2014
NCT00609765Terminated1Est. Mar 2008
NCT00810719Completed30Est. Dec 2013
+2 more trials
ImmunityBio
ImmunityBioSAN DIEGO, CA
5 programs
4
1
N-803Phase 21 trial
ALT-803Phase 1/21 trial
Aldoxorubicin HClPhase 1/21 trial
Aldoxorubicin HClPhase 1/21 trial
CyclophosphamidePhase 1/21 trial
Active Trials
NCT03329248Terminated6Est. Nov 2019
NCT03586869Terminated3Est. Aug 2019
NCT03387098Terminated4Est. Jan 2019
+2 more trials
Mereo BioPharma
Mereo BioPharmaUK - London
4 programs
3
1
DemcizumabPhase 2Monoclonal Antibody1 trial
DemcizumabPhase 1Monoclonal Antibody1 trial
OMP-54F28, Nab-Paclitaxel and GemcitabinePhase 11 trial
VantictumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01189929CompletedEst. Dec 2016
NCT02050178CompletedEst. Jun 2017
NCT02005315CompletedEst. Nov 2017
+1 more trials
Genomics
GenomicsUK - Oxford
4 programs
1
3
MinnelidePhase 21 trial
ParicalcitolPhase 21 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
Ascorbic AcidPhase 1/21 trial
Active Trials
NCT03410030Completed27Est. Jan 2022
NCT03117920Completed19Est. Jul 2019
NCT03415854Completed11Est. Dec 2023
+1 more trials
Alliance Pharmaceuticals
4 programs
4
ISIS 2503Phase 21 trial
bevacizumabPhase 2Monoclonal Antibody5 trials
cisplatinPhase 21 trial
gemcitabine hydrochloridePhase 25 trials
Active Trials
NCT00006467Completed48Est. Jan 2004
NCT00571740Withdrawn0
NCT07011550Suspended7Est. Jul 2030
+9 more trials
Ipsen
IpsenChina - Tianjin
3 programs
2
1
nal-IRIPhase 21 trial
5-FUPhase 11 trial
Xilonix plus Onivyde and 5FUPhase 1
Active Trials
NCT03883919Completed20Est. Jul 2022
NCT02551991Completed56Est. Feb 2021
CT
3 programs
1
2
TQB2916 InjectionPhase 21 trial
anlotinib + benmelstobart + nab-paclitaxel + gemcitabinePhase 21 trial
AL2846 capsulesPhase 1/21 trial
Active Trials
NCT06278493CompletedEst. May 2023
NCT06962267RecruitingEst. Oct 2027
NCT06621095Not Yet RecruitingEst. Dec 2026
Abbott
2 programs
1
VolociximabPhase 2Monoclonal Antibody1 trial
Ensure SurgicalN/A1 trial
Active Trials
NCT03244683Terminated8Est. Aug 2018
NCT00401570Completed40Est. Jun 2008
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
VolociximabPhase 2Monoclonal Antibody
ABBV-927Phase 11 trial
Active Trials
NCT04807972Terminated40Est. Mar 2024
Novartis
2 programs
1
1
mFOLFIRINOXPhase 21 trial
BYL719Phase 15 trials
Active Trials
NCT02298595Withdrawn0Est. Aug 2024
NCT02734615Terminated199Est. Sep 2021
NCT02550743Terminated7Est. Nov 2018
+3 more trials
Taiho Oncology
Taiho OncologyNJ - Princeton
2 programs
1
1
TAS-102Phase 21 trial
LonsurfPhase 11 trial
Active Trials
NCT04046887TerminatedEst. Oct 2023
NCT02921737TerminatedEst. Jul 2020
Bristol Myers Squibb
2 programs
2
CyclophosphamidePhase 21 trial
CyclophosphamidePhase 25 trials
Active Trials
NCT02451982Active Not Recruiting76Est. May 2026
NCT07335562Not Yet Recruiting92Est. Nov 2030
NCT07015242Recruiting65Est. Dec 2028
+3 more trials
Bayer
2 programs
2
GemcitabinePhase 25 trials
regorafenibPhase 2Small Molecule1 trial
Active Trials
NCT04156828Terminated12Est. Jun 2023
NCT03052933Completed28Est. Jul 2021
NCT02631590Completed24Est. Mar 2021
+3 more trials
VP
1 program
1
AVN944Phase 21 trial
Active Trials
NCT00493441Terminated28Est. Dec 2009

+29 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
EisaiDalteparin
Bristol Myers SquibbCyclophosphamide
AstellasSetidegrasib
REVOLUTION Medicinesdaraxonrasib
Qilu PharmaceuticalQLS31905
Bristol Myers SquibbCyclophosphamide
REVOLUTION MedicinesRMC-6236
Bristol Myers SquibbCyclophosphamide
Bristol Myers SquibbCyclophosphamide
Bristol Myers SquibbCyclophosphamide
Bausch HealthMethylnaltrexone bromide
Providence TherapeuticsCefoxitin
Alliance Pharmaceuticalsbevacizumab
Alliance Pharmaceuticalsbevacizumab
Bristol Myers SquibbCyclophosphamide

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 10,734 patients across 50 trials

NCT00966277EisaiDalteparin

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Start: Apr 2010Est. completion: Sep 201487 patients
Phase 4Completed
NCT07335562Bristol Myers SquibbCyclophosphamide

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Start: Apr 2026Est. completion: Nov 203092 patients
Phase 3Not Yet Recruiting
NCT07409272AstellasSetidegrasib

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Start: Feb 2026Est. completion: Aug 2029614 patients
Phase 3Recruiting
NCT07252232REVOLUTION Medicinesdaraxonrasib

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Start: Dec 2025Est. completion: Jul 2030500 patients
Phase 3Recruiting
NCT07079228Qilu PharmaceuticalQLS31905

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Start: Sep 2025Est. completion: Sep 2030
Phase 3Recruiting
NCT06615479Bristol Myers SquibbCyclophosphamide

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Start: Mar 2025Est. completion: Jun 2032440 patients
Phase 3Recruiting
NCT06625320REVOLUTION MedicinesRMC-6236

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Start: Oct 2024Est. completion: Dec 2027501 patients
Phase 3Active Not Recruiting
NCT06313996Bristol Myers SquibbCyclophosphamide

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Start: Mar 2024Est. completion: Oct 2031300 patients
Phase 3Not Yet Recruiting
NCT06205290Bristol Myers SquibbCyclophosphamide

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Start: Jan 2024Est. completion: Oct 20310
Phase 3Withdrawn
NCT06045806Bristol Myers SquibbCyclophosphamide

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Start: Oct 2023Est. completion: Nov 202979 patients
Phase 3Active Not Recruiting
NCT04151719Bausch HealthMethylnaltrexone bromide

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Start: Feb 2020Est. completion: Feb 2024
Phase 3Withdrawn
NCT03269994Providence TherapeuticsCefoxitin

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Start: Nov 2017Est. completion: Jan 2025
Phase 3Completed
NCT01279681Alliance Pharmaceuticalsbevacizumab

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Start: Jan 2011Est. completion: Nov 201432 patients
Phase 3Terminated
NCT01167725Alliance Pharmaceuticalsbevacizumab

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Start: Aug 2010Est. completion: Jan 2012340 patients
Phase 3Terminated
NCT00789581Bristol Myers SquibbCyclophosphamide

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Start: Dec 2008Est. completion: Nov 2016614 patients
Phase 3Completed
NCT00789633AB ScienceMasitinib

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Start: Nov 2008Est. completion: Aug 2012
Phase 3Completed
NCT00237575BayerGemcitabine

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

Start: Nov 2005Est. completion: Mar 2006100 patients
Phase 3Terminated
NCT00265850Alliance Pharmaceuticalsbevacizumab

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Start: Nov 2005Est. completion: Jan 20182,334 patients
Phase 3Completed
NCT00129389Bristol Myers SquibbCyclophosphamide

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Start: Sep 2003Est. completion: Oct 20131,925 patients
Phase 3Completed
NCT00040092Aptose BiosciencesVirulizin®

A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

Start: Jul 2002
Phase 3Completed
NCT00813696Verona Pharmagemcitabine

Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer

Start: Apr 2002Est. completion: Sep 2009
Phase 3Unknown
NCT00040183AstellasTarceva

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Start: Nov 2001Est. completion: Jan 2004569 patients
Phase 3Completed
NCT00023972Daiichi Sankyoexatecan mesylate

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Start: Jul 2001Est. completion: Apr 2005
Phase 3Completed
NCT00033735Eisaifluorouracil

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Start: Jan 2000158 patients
Phase 3Completed
NCT00129922Bristol Myers SquibbCyclophosphamide

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Start: Nov 1999Est. completion: Dec 20071,289 patients
Phase 3Completed
NCT00005870Astex Pharmaceuticalsfluorouracil

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Start: Mar 1999
Phase 3Unknown
NCT00005869Astex Pharmaceuticalsgemcitabine hydrochloride

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Start: Nov 1998
Phase 3Unknown
NCT00005871Astex Pharmaceuticalsfluorouracil

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Start: Nov 1998
Phase 3Unknown
NCT04083651Bausch HealthMethylnaltrexone bromide

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Start: Jan 2020Est. completion: Oct 2023
Phase 2/3Withdrawn
NCT00113256Astex PharmaceuticalsRubitecan

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Start: Feb 2005
Phase 2/3Terminated
NCT00571740Alliance Pharmaceuticalsbevacizumab

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

0
Phase 2Withdrawn
NCT07015242Bristol Myers SquibbCyclophosphamide

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Start: Nov 2025Est. completion: Dec 202865 patients
Phase 2Recruiting
NCT07011550Alliance Pharmaceuticalsbevacizumab

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Start: Aug 2025Est. completion: Jul 20307 patients
Phase 2Suspended
NCT07015983Bristol Myers SquibbCyclophosphamide

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Start: Jul 2025Est. completion: Jun 203289 patients
Phase 2Recruiting
NCT06962267Chia Tai TianQing Pharmaceutical GroupTQB2916 Injection

A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

Start: Apr 2025Est. completion: Oct 2027
Phase 2Recruiting
NCT06621095Chia Tai TianQing Pharmaceutical Groupanlotinib + benmelstobart + nab-paclitaxel + gemcitabine

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Start: Oct 2024Est. completion: Dec 2026
Phase 2Not Yet Recruiting
NCT06491472AkesobioIvonescimab

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Start: Jul 2024Est. completion: Jul 2027
Phase 2Recruiting
NCT05776524TheraBionicNab paclitaxel

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Start: Jun 2023Est. completion: Jul 2029
Phase 2Recruiting
NCT05546411NovartismFOLFIRINOX

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Start: Jan 2023Est. completion: Oct 20238 patients
Phase 2Terminated
NCT05114213Heidelberg PharmaSBRT

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

Start: Dec 2021Est. completion: Nov 20259 patients
Phase 2Terminated
NCT04536077Celldex TherapeuticsCDX-301

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Start: Aug 2021Est. completion: Nov 202316 patients
Phase 2Terminated
NCT04571489Lee's PharmaceuticalGimatecan

A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer

Start: Dec 2020Est. completion: Dec 202360 patients
Phase 2Unknown
NCT04543071RegeneronMotixafortide

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Start: Nov 2020Est. completion: Aug 202810 patients
Phase 2Recruiting
NCT04390399ImmunityBioN-803

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Start: Jul 2020Est. completion: May 2026328 patients
Phase 2Active Not Recruiting
NCT03415854GenomicsParicalcitol

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Start: Jan 2018Est. completion: Dec 202311 patients
Phase 2Completed
NCT03331562GenomicsPembrolizumab

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Start: Dec 2017Est. completion: Jul 202024 patients
Phase 2Completed
NCT03190265Bristol Myers SquibbCyclophosphamide

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Start: Dec 2017Est. completion: Aug 202361 patients
Phase 2Completed
NCT02921737Taiho OncologyTAS-102

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Start: Nov 2017Est. completion: Jul 2020
Phase 2Terminated
NCT03252600Bristol Myers SquibbCyclophosphamide

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Start: Aug 2017Est. completion: Dec 202353 patients
Phase 2Unknown
NCT03117920GenomicsMinnelide

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

Start: Apr 2017Est. completion: Jul 201919 patients
Phase 2Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs — potential near-term approvals
10 actively recruiting trials targeting 10,734 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)